Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
Why it matters
Adial Pharmaceuticals will implement a 1-for-25 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, with trading adjusted on February 6, 2026.
Expected market reaction
Market impact analysis based on neutral sentiment with 80% confidence.
Evidence trail
Evidence
AI provenance
Technical identifiers
- Provider tag
- groq-llama-3.1-8b-instant
- Analysis version
- groq-llama-3.1-8b-instant
- Article id
- 41133
Original source
Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026GLEN ALLEN, Va., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will effect a 1-for-25 reverse stock split (the “Reverse Split”) of its common stock, par value $0.001 per share (“Common Stock”), that
Read the full article on Yahoo Finance
Original article published by Yahoo Finance on February 4, 2026. Analysis and insights provided by AnalystMarkets AI.